Teva CEO Schultz: ‘Proof Is In The Pudding’ For US Biosimilars

Biosimilars Key For Teva As It Chases Mid-Single Digit Sales Growth

 
• By Dean Rudge
  
PumpkinPie
Teva is "very happy about the situation we see in the biosimilar space," according to CEO Kåre Schultz • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products